Hyperthermia with Chemotherapy for Unresectable Gastric Cancer in a Patient with a Vagus Nerve Stimulator Implant: A Case Report.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
17 Aug 2021
17 Aug 2021
Historique:
entrez:
17
8
2021
pubmed:
18
8
2021
medline:
19
8
2021
Statut:
epublish
Résumé
BACKGROUND Radiofrequency (RF) hyperthermia is commonly used as an adjunct to established treatment modalities such as chemotherapy and radiotherapy for the management of cancer patients. This case report aims to introduce the use of hyperthermia, in combination with chemotherapy, for the treatment of unresectable gastric cancer in a patient implanted with a vagus nerve stimulator (VNS). CASE REPORT A 55-year-old man with dermatomyositis, laryngeal squamous cell carcinoma in situ and double synchronous gastric cancer was found to have unresectable gastric disease during surgery despite neoadjuvant chemotherapy. Postoperatively, he received chemotherapy with RF hyperthermia. The patient had a VNS implant to treat epileptic seizures. VNS failure due to RF hyperthermia was an area of significant concern, and the procedures were completed with a full preparation to manage epileptic seizures in the event of its anticipated occurrence. Twenty-one thermotherapies were performed over 21 weeks. After 3 courses of S-1 chemotherapy (12 weeks) with RF hyperthermia without any adverse events, the regimen was changed to S-1+ CDDP combination chemotherapy (SP) and RF hyperthermia. The patient continued to receive treatment with a decrease in the size of the primary gastric tumors as well as lymph node metastases, without major adverse events, until he died due to disseminated disease. CONCLUSIONS We report the first case of unresectable gastric cancer with VNS implants in which chemo-hyperthermal therapy was safe and successful. This case report highlights the importance of providing a multidisciplinary treatment with appropriate measures for patients with intractable cancer who have received special treatments for underlying comorbidities.
Identifiants
pubmed: 34400601
pii: 931564
doi: 10.12659/AJCR.931564
pmc: PMC8380855
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e931564Références
Cancer Med. 2015 Jun;4(6):834-43
pubmed: 25664976
J Huazhong Univ Sci Technolog Med Sci. 2013 Dec;33(6):870-876
pubmed: 24337851
Gastric Cancer. 2020 Jul;23(4):677-688
pubmed: 32036492
J Cancer Res Clin Oncol. 2014 Feb;140(2):319-28
pubmed: 24366758
Int J Hyperthermia. 2019 Nov;36(sup1):4-9
pubmed: 31795827
R I Med J (2013). 2020 Apr 1;103(3):33-37
pubmed: 32236159
Int J Hyperthermia. 2016 Jun;32(4):455-63
pubmed: 27050781
Integr Cancer Ther. 2018 Jun;17(2):558-561
pubmed: 28745084
Am J Physiol. 1985 Jul;249(1 Pt 2):H133-40
pubmed: 4014479
Int J Hyperthermia. 2012;28(6):528-42
pubmed: 22690925
Lancet Oncol. 2002 Aug;3(8):487-97
pubmed: 12147435
Onco Targets Ther. 2020 Feb 26;13:1751-1756
pubmed: 32161470
Evid Based Complement Alternat Med. 2013;2013:672873
pubmed: 23662149
Cancer Res Treat. 2019 Jul;51(3):841-850
pubmed: 31048663
Eur J Radiol. 2011 Sep;79(3):343-6
pubmed: 20434862
Front Immunol. 2015 Nov 20;6:588
pubmed: 26635802
Cancer. 2011 Mar 15;117(6):1163-71
pubmed: 21381009
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):501-510
pubmed: 31101534
Int J Hyperthermia. 2017 Feb;33(1):25-33
pubmed: 27411731
Semin Oncol. 2014 Dec;41(6):714-29
pubmed: 25499632
N Engl J Med. 1992 Feb 6;326(6):363-7
pubmed: 1729618
Gastric Cancer. 2018 Mar;21(2):315-323
pubmed: 28616743
Int J Hyperthermia. 2015;31(6):609-14
pubmed: 25975276
Lancet Oncol. 2008 Mar;9(3):215-21
pubmed: 18282805
Am J Case Rep. 2020 Nov 03;21:e926647
pubmed: 33141812
Integr Cancer Ther. 2018 Dec;17(4):1297-1303
pubmed: 30193538
CA Cancer J Clin. 2009 Mar-Apr;59(2):73-98
pubmed: 19258446